November 10 Report Does Not Confirm Another Upgrade to Gedeon Richter’s Outlook
Key Facts
A further upgrade to Gedeon Richter’s 2026 outlook could not be verified in the November 10 news, so it cannot be confirmed that the company issued a new revision to its financial guidance that day. The company had set November 10, 2026, as the date for publishing its first nine-month results, according to its financial calendar. The latest documented change in the available evidence remains the clean operating earnings guidance for the pharmaceuticals segment that the company announced in August. It also could not be verified that the alleged revision was based on revenue or earnings exceeding previous estimates. The available figures therefore center on first-half results and the guidance the company announced at the time.
On August 7, Richter raised its 2026 Clean EBIT growth guidance for the pharmaceuticals segment, measured at constant exchange rates, to double-digit growth. In May, the company had forecast high-single-digit growth in both revenue and Clean EBIT on the same basis. That makes the August announcement a documented change to guidance during the year, not evidence of another revision in November. Both guidance figures concern operating metrics measured at constant exchange rates, while reported figures can move differently after currency translation. The available information did not include a specific new figure for full-year revenue or net profit.
First-half results showed pharmaceuticals revenue growth of 8.7% at constant exchange rates, but reported revenue fell 0.5% year over year to 455 billion Hungarian forints. The company attributed constant-currency revenue growth to performance in its central nervous system and biotechnology segments, alongside improving momentum in women’s healthcare and generics in the second quarter. The figures highlight the difference between the operating picture and reported revenue after the impact of currencies. These results alone do not establish that guidance was raised again in November. They also cover first-half performance, not the nine-month results scheduled for release on November 10.
For operating profitability, Clean EBIT in the pharmaceuticals segment rose 21% at constant exchange rates in the first half, while the reported figure increased 3% to 151.8 billion Hungarian forints. The company said performance benefited from the outperformance of cariprazine and gains from multiyear efficiency initiatives. This reported operating growth compares with constant-currency revenue growth of 8.7%; growth rates calculated at constant exchange rates should not be confused with changes in reported figures. The results provide context for the August guidance that raised the Clean EBIT target to double-digit growth. They do not, on their own, prove that the company revised its guidance again in November.
At the net-profit level, Richter recorded 103.5 billion Hungarian forints in the first half, down 14% year over year. The company said foreign-exchange losses of 27.1 billion forints weighed on the period. This shows that improved operating metrics did not translate into the same direction of change in reported net profit during the first six months. In an earlier comparison, pharmaceuticals revenue rose 7% to 669 billion forints in the first nine months of 2025, while net profit fell 7% to 163 billion forints. In the third quarter of 2025, pharmaceuticals revenue declined 1% to 211.2 billion forints, with the company then citing supply and inventory problems at distributors and a higher comparison base in generics as pressures.
In November 2025, the company said it expected revenue of about 2.3 billion euros and Clean EBIT growth of between 8% and 10% for that year, after a slowdown in the third quarter. Chief Executive Gábor Orbán said at the time that most of the generics and contract manufacturing challenges that had weighed on the third quarter could ease or disappear in the following months. Those forecasts and comments relate to 2025 and are not 2026 targets. The next relevant step is the first nine-month 2026 results report, which Richter’s calendar scheduled for November 10. The available information does not include details of that report or independent confirmation of a further outlook upgrade on its publication date.